TerminatedPhase 3NCT01604005
PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma
Studying Pleural mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Brynn Chappell
- Principal Investigator
- Corinne Faivre-FinnThe Christie NHS Foundation Trust
- Intervention
- Prophylactic Irradiation of Tracts (PIT)(radiation)
- Enrollment
- 375 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2017
Study locations (30)
- Tameside General Hospital, Ashton-under-Lyne, United Kingdom
- Basingstoke & North Hampshire Hospital, Basingstoke, United Kingdom
- Clatterbridge Cancer Centre, Bebington, United Kingdom
- Belfast City Hospital, Belfast, United Kingdom
- University Hospital Birmingham, Birmingham, United Kingdom
- Royal Blackburn, Blackburn, United Kingdom
- Blackpool Victoria Hospital, Blackpool, United Kingdom
- Royal Bolton Hospital, Bolton, United Kingdom
- Pilgrim Hospital, Boston, United Kingdom
- Bradford Royal Infirmary, Bradford, United Kingdom
- Queen's Hospital, Burton, United Kingdom
- Addenbrookes, Cambridge, United Kingdom
- Kent Oncology Centre, Canterbury, United Kingdom
- University Hospital of North Tees, Cleveland, United Kingdom
- University Hospital Coventry, Coventry, United Kingdom
- +15 more locations on ClinicalTrials.gov
Collaborators
The Christie NHS Foundation Trust
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01604005 on ClinicalTrials.govOther trials for Pleural mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07192900Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseDavid Bartlett, MD
- RECRUITINGNANCT07126509Partial Pleurectomy (Surgery) for Unresectable Pleural MesotheliomaUniversity of Chicago
- RECRUITINGPHASE1, PHASE2NCT07121374NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility StudyUniversity Hospital, Antwerp
- RECRUITINGPHASE1NCT06885697Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06840834Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and ChemotherapyIntergroupe Francophone de Cancerologie Thoracique
- RECRUITINGPHASE2NCT06875076Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural MesotheliomaThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06790082The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural MesotheliomaAalborg University Hospital
- RECRUITINGPHASE1NCT06566079Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid TumorsInSilico Medicine Hong Kong Limited